Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology | Musculoskeletal
Disease Category: Multiple Sclerosis
Trial Information
New Oral medication for reducing the rate of clinical relapses in patients with Relapsing Remitting Multiple Sclerosis (MS)
This is a two year blinded study comparing two different doses of an oral medication compared to placebo or Copaxone (Daily injections). The primary objective is to determine whether the investigational medication is effective in reducing the rate of clinical relapses.
Major Inclusion/Exclusion Criteria:
- Ages 18-55
- Confirmed diagnosis of Relapsing Remitting Multiple Sclerosis
- At least one relapse within the last 12 months
- Must be able to walk unassisted 200 yards
- Must NEVER have taken Copaxone
- Must be off interferons (Avonex, Betaseron & Rebif) for 3 months
Alpine Clinical Research Center
1000 Alpine Avenue, Suite 200
Boulder, CO 80304
Phone: 303-443-7229 ext. 108
EMail: Deb@alpineresearch.com
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
